Efficacy and safety of rosuvastatin and atorvastatin for treatment of coronary heart disease:A Meta-analysis

Objective To systematic evaluate the efficacy and safety of rosuvastatin(RSV) and atorvastatin(ATV)for treatment of coronary atherosclerotic heart disease lipid.Methods The PUBMED,VIP,CNKI,Wanfang data were collected and randomized controlled trials(RCT) of efficacy and safety of RSV and ATV in treatment of coronary heart disease,while recourse included literature references.Retrieval time was from 2003 to 2013.Jadad score were used for literature evaluation and information extraction.Statistical analysis was performed using RevMan5.0.25 software.Results A total of 10 trials were included.Mela-analysis demonstrated that:(1) LDL-C:RSV compared with the ATV,the difference was not statistically significant(MD=-3.99,95%CI- 9.34- 1.37,P 0.05);(2) HDL-C;RSV compared with the ATV,the difference was statistically significant(MD = 1.80,95%CI 1.74-1.86,P 0.01);(3) TG:RSV compared with the ATV,the difference was not statistically significant(MD=9.31,95%CI-3.74- 22.37,P 0.05);(4) TC:RSV compared with the ATV,the difference was not statistically significant(MD =-1.21,95%CI- 12.39-9.95,P 0.05);(5) Adverse event(AE) rates ? RSV compared with the ATV,the difference was not statistically significant(OR = 1.02,95%CI 0.80- 1.29,P 0.05).Conclusion Compaied with atorvastatin,rosuvastatin reveals no advantage in improving LDL-C,TG,TC and AE incidence in patients with coronary artery disease.